Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Oncotarget

Volumn 7, Issue 20, 2016, Pages 29321-29332

  Fanale, Daniele ^a   Amodeo, Valeria ^a   Bazan, Viviana ^a   Insalaco, Lavinia ^a   Incorvaia, Lorena ^a   Barraco, Nadia ^a   Castiglia, Marta ^a   Rizzo, Sergio ^a   Santini, Daniele ^b   Giordano, Antonio ^c   Castorina, Sergio ^d,e   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c Temple University   (United States)

^d Fondazione Mediterranea GB Morgagni   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

Bone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid

Indexed keywords

JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; TRANSCRIPTOME;

ACTIN FILAMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; INCUBATION TIME; MCF 7 CELL LINE; MICROARRAY ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKBR3 CELL LINE; UPREGULATION; BREAST TUMOR; DRUG EFFECTS; GENETICS; MCF-7 CELL LINE;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; DIPHOSPHONATES; GENE EXPRESSION PROFILING; HUMANS; IMIDAZOLES; MCF-7 CELLS; TRANSCRIPTOME;

EID: 84969820522     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8722     Document Type: Article

References (67)

1. Fanale D, Bazan V, Caruso S, Castiglia M, Bronte G, Rolfo C, Cicero G, Russo A. Hypoxia and human genome stability: downregulation of BRCA2 expression in breast cancer cell lines. Biomed Res Int. 2013; 2013:746858.
2. Russo A, Calo V, Bruno L, Schiro V, Agnese V, Cascio S, Foddai E, Fanale D, Rizzo S, Di Gaudio F, Gulotta E, Surmacz E, Di Fede G, et al. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation? Breast cancer research and treatment. 2009; 113:67-70.
3. Aft R. Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid. Int J Womens Health. 2012; 4:569-576.
4. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002; 2:584-593.
5. Zhou WB, Zhang PL, Liu XA, Yang T, He W. Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis. Journal of experimental & clinical cancer research. 2011; 30:72.
6. Iozzo RV, Karamanos N. Proteoglycans in health and disease: emerging concepts and future directions. FEBS J. 2010; 277:3863.
7. Syggelos SA, Aletras AJ, Smirlaki I, Skandalis SS. Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome. Biomed Res Int. 2013; 2013:230805.
8. Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010; 36:615-620.
9. Facchini G, Caraglia M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, Budillon A, Iaffaioli RV, Zeppetella GL. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). Journal of experimental & clinical cancer research: CR. 2007; 26:307-312.
10. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 1998; 16:3890-3899.
11. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998; 13:581-589.
12. Kopecka J, Porto S, Lusa S, Gazzano E, Salzano G, Giordano A, Desiderio V, Ghigo D, Caraglia M, De Rosa G, Riganti C. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells. Oncotarget. 2015; 6:31461-31478. doi: 10.18632/ oncotarget.5058.
13. Coxon FP, Rogers MJ. The role of prenylated small GTPbinding proteins in the regulation of osteoclast function. Calcif Tissue Int. 2003; 72:80-84.
14. Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol. 2010; 37 Suppl 2:S30-40.
15. Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010; 102:1099-1105.
16. Zarogoulidis K, Boutsikou E, Zarogoulidis P, Eleftheriadou E, Kontakiotis T, Lithoxopoulou H, Tzanakakis G, Kanakis I, Karamanos NK. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer. 2009; 125:1705-1709.
17. Dedes PG, Gialeli C, Tsonis AI, Kanakis I, Theocharis AD, Kletsas D, Tzanakakis GN, Karamanos NK. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid. Biochim Biophys Acta. 2012; 1820:1926-1939.
18. Sewing L, Steinberg F, Schmidt H, Goke R. The bisphosphonate zoledronic acid inhibits the growth of HCT- 116 colon carcinoma cells and induces tumor cell apoptosis. Apoptosis. 2008; 13:782-789.
19. Mani J, Vallo S, Barth K, Makarevic J, Juengel E, Bartsch G, Wiesner C, Haferkamp A, Blaheta RA. Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. Prostate Cancer Prostatic Dis. 2012; 15:250-255.
20. Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, Amadori D. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012; 12:48.
21. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, Santini D, Caraglia M. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther. 2012; 13:1491-1500.
22. Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011; 29:533-541.
23. Nussbaumer O, Gruenbacher G, Gander H, Thurnher M. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gammadelta T lymphocytes. Blood. 2011; 118:2743-2751.
24. Rietkotter E, Menck K, Bleckmann A, Farhat K, Schaffrinski M, Schulz M, Hanisch UK, Binder C, Pukrop T. Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion. Oncotarget. 2013; 4:1449-1460. doi: 10.18632/oncotarget.1201.
25. Nienhuis HH, Arjaans M, Timmer-Bosscha H, de Vries EG, Schroder CP. Human stromal cells are required for an antibreast cancer effect of zoledronic acid. Oncotarget. 2015; 6:24436-24447. doi: 10.18632/oncotarget.4421.
26. Insalaco L, Di Gaudio F, Terrasi M, Amodeo V, Caruso S, Corsini LR, Fanale D, Margarese N, Santini D, Bazan V, Russo A. Analysis of molecular mechanisms and antitumoural effects of zoledronic acid in breast cancer cells. J Cell Mol Med. 2012; 16:2186-2195.
27. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136:215-233.
28. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. Journal of experimental & clinical cancer research. 2012; 31:38.
29. Ambros V. The functions of animal microRNAs. Nature. 2004; 431:350-355.
30. Amodeo V, Bazan V, Fanale D, Insalaco L, Caruso S, Cicero G, Bronte G, Rolfo C, Santini D, Russo A. Effects of antimiR- 182 on TSP-1 expression in human colon cancer cells: there is a sense in antisense? Expert Opin Ther Targets. 2013; 17:1249-1261.
31. Wang C, Zheng X, Shen C, Shi Y. MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. Journal of experimental & clinical cancer research. 2012; 31:58.
32. Malek E, Jagannathan S, Driscoll JJ. Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget. 2014; 5:8027-8038. doi: 10.18632/oncotarget.2469.
33. Caruso S, Bazan V, Rolfo C, Insalaco L, Fanale D, Bronte G, Corsini LR, Rizzo S, Cicero G, Russo A. MicroRNAs in colorectal cancer stem cells: new regulators of cancer stemness? Oncogenesis. 2012; 1:e32.
34. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65:7065-7070.
35. Ma L, Weinberg RA. Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends in genetics: TIG. 2008; 24:448-456.
36. Rahim F, Hajizamani S, Mortaz E, Ahmadzadeh A, Shahjahani M, Shahrabi S, Saki N. Molecular regulation of bone marrow metastasis in prostate and breast cancer. Bone marrow research. 2014; 2014:405920.
37. Santini D, Vincenzi B, Pantano F, Tonini G, Bertoldo F. Targeting bone metastases starting from the preneoplastic niche: home sweet home. Breast cancer research: BCR. 2011; 13:111.
38. Croset M, Santini D, Iuliani M, Fioramonti M, Zoccoli A, Vincenzi B, Tonini G, Pantano F. MicroRNAs and bone metastasis: a new challenge. Molecules. 2014; 19:10115-10128.
39. Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Disease markers. 2013; 35:369-387.
40. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol. 2009; 174:1131-1138.
41. Corsini LR, Bronte G, Terrasi M, Amodeo V, Fanale D, Fiorentino E, Cicero G, Bazan V, Russo A. The role of microRNAs in cancer: diagnostic and prognostic biomarkers and targets of therapies. Expert Opin Ther Targets. 2012; 16 Suppl 2:S103-109.
42. Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B, Stahler C, Meese E, Keller A. Distribution of miRNA expression across human tissues. Nucleic Acids Res. 2016.
43. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M, Hatzigeorgiou AG. DIANA-mirPath: Integrating human and mouse microRNAs in pathways. Bioinformatics. 2009; 25:1991-1993.
44. Li S, De Souza P. Ras Isoprenylation and pAkt Inhibition by Zoledronic Acid and Fluvastatin Enhances Paclitaxel Activity in T24 Bladder Cancer Cells. Cancers (Basel). 2011; 3:662-674.
45. Lan YC, Chang CL, Sung MT, Yin PH, Hsu CC, Wang KC, Lee HC, Tseng LM, Chi CW. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells. Anticancer Res. 2013; 33:3807-3814.
46. Chang J, Wang W, Zhang H, Hu Y, Yin Z. Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells. Oncol Lett. 2012; 4:299-304.
47. Kaiser T, Teufel I, Geiger K, Vater Y, Aicher WK, Klein G, Fehm T. Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells. Breast cancer research and treatment. 2013; 140:35-48.
48. Vincenzi B, Santini D, Dicuonzo G, Battistoni F, Gavasci M, La Cesa A, Grilli C, Virzi V, Gasparro S, Rocci L, Tonini G. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005; 25:144-151.
49. Ory B, Blanchard F, Battaglia S, Gouin F, Redini F, Heymann D. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007; 71:333-343.
50. Iguchi T, Miyakawa Y, Saito K, Nakabayashi C, Nakanishi M, Saya H, Ikeda Y, Kizaki M. Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J Oncol. 2007; 31:285-291.
51. Schech AJ, Kazi AA, Gilani RA, Brodie AH. Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-kappaB. Mol Cancer Ther. 2013; 12:1356-1366.
52. Nogawa M, Yuasa T, Kimura S, Kuroda J, Segawa H, Sato K, Yokota A, Koizumi M, Maekawa T. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res. 2005; 15:1-9.
53. Fanale D, Bazan V, Corsini LR, Caruso S, Insalaco L, Castiglia M, Cicero G, Bronte G, Russo A. HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions. Breast cancer research and treatment. 2013; 140:505-517.
54. Fanale D, Amodeo V, Corsini LR, Rizzo S, Bazan V, Russo A. Breast cancer genome-wide association studies: there is strength in numbers. Oncogene. 2012; 31:2121-2128.
55. Jia XH, Du Y, Mao D, Wang ZL, He ZQ, Qiu JD, Ma XB, Shang WT, Ding D, Tian J. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages. Oncotarget. 2015; 6:26018-26028. doi: 10.18632/oncotarget.4658.
56. Clezardin P. Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep. 2013; 2:267.
57. Jia X, Hong Q, Lei L, Li D, Li J, Mo M, Wang Y, Shao Z, Shen Z, Cheng J, Liu G. Basal and therapy-driven hypoxiainducible factor-1alpha confers resistance to endocrine therapy in estrogen receptor-positive breast cancer. Oncotarget. 2015; 6:8648-8662. doi: 10.18632/oncotarget.3257.
58. Almubarak H, Jones A, Chaisuparat R, Zhang M, Meiller TF, Scheper MA. Zoledronic acid directly suppresses cell proliferation and induces apoptosis in highly tumorigenic prostate and breast cancers. J Carcinog. 2011; 10:2.
59. Li XY, Lin YC, Huang WL, Hong CQ, Chen JY, You YJ, Li WB. Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. Med Oncol. 2012; 29:714-720.
60. Lin H, Dai T, Xiong H, Zhao X, Chen X, Yu C, Li J, Wang X, Song L. Unregulated miR-96 induces cell proliferation in human breast cancer by downregulating transcriptional factor FOXO3a. PLoS One. 2010; 5:e15797.
61. Liang Z, Bian X, Shim H. Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast cancer research and treatment. 2014; 146:535-542.
62. Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, Shim H. Involvement of miR- 326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 2010; 79:817-824.
63. Pandey AK, Zhang Y, Zhang S, Li Y, Tucker-Kellogg G, Yang H, Jha S. TIP60-miR-22 axis as a prognostic marker of breast cancer progression. Oncotarget. 2015; 6:41290- 41306. doi: 10.18632/oncotarget.5636.
64. Di Fiore R, Fanale D, Drago-Ferrante R, Chiaradonna F, Giuliano M, De Blasio A, Amodeo V, Corsini LR, Bazan V, Tesoriere G, Vento R, Russo A. Genetic and molecular characterization of the human osteosarcoma 3AB-OS cancer stem cell line: a possible model for studying osteosarcoma origin and stemness. J Cell Physiol. 2013; 228:1189-1201.
65. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG. DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res. 2012; 40:W498-504.
66. Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011; 39:D152-157.
67. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012; 40:D109-114.